A validated HPLC assay to monitor riluzole plasma or serum concentrations in patients with amyotrophic lateral sclerosis

Biomedical Chromatography

Volumn 18, Issue 9, 2004, Pages 723-726

  van Kan, H J M ^a   Spieksma, M ^a   Groeneveld, G J ^b   Sastre Torano J ^a   van den Berg, L H ^b   Guchelaar, H J ^c  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

2 amino 6 trifluoromethoxy benzothiazole; Glutamate antagonist; HPLC UV detection; Therapeutic drug monitoring

Indexed keywords

BODY FLUIDS; EXTRACTION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; NEURODEGENERATIVE DISEASES; PATIENT MONITORING;

2-AMINO-6-TRIFLUOROMETHOXY-BENZOTHIAZOLE; AMYOTROPHIC LATERAL SCLEROSIS; BENZOTHIAZOLES; GLUTAMATE ANTAGONIST; HPLC-UV; HPLC-UV DETECTION; PLASMA CONCENTRATION; RILUZOLE; THERAPEUTIC DRUG MONITORING; UV DETECTION;

DICHLOROMETHANE;

AMITRIPTYLINE; BERGAPTEN; CAFFEINE; DICHLOROMETHANE; FLUCLOXACILLIN; IBUPROFEN; NORTRIPTYLINE; OMEPRAZOLE; PARACETAMOL; PAROXETINE; RILUZOLE; SALICYLIC ACID; TRIMETHOPRIM;

ACCURACY; AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG ISOLATION; DRUG MONITORING; DRUG STABILITY; DRUG STRUCTURE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; RADIATION DETECTION; REVERSED PHASE LIQUID CHROMATOGRAPHY; SENSITIVITY AND SPECIFICITY; STORAGE TEMPERATURE; ULTRAVIOLET RADIATION; VALIDATION PROCESS;

EID: 9944242095     PISSN: 02693879     EISSN: None     Source Type: Journal    
DOI: 10.1002/bmc.384     Document Type: Article

References (5)

1. Bensimon G, Lacomblez L and Meininger V. A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. New England Journal of Medicine 1994; 330: 585-591.
2. Bruno R, Vivier N, Montay G, Le Liboux A, Powe LK, Delumeau JC and Rhodes GR. Population pharmacokinetics of riluzole in patients with amyotrophic lateral sclerosis. Clinical Pharmacological Therapy 1997; 62: 518-526.
3. Lacomblez L, Bensimon G, Leigh PN, Guillet P, Powe L, Durrleman S, Delumeau JC and Meininger V. A confirmatory dose-ranging study of riluzole in ALS. ALS/Riluzole Study Group-II. Neurology 1996; 47(Suppl. 4): S242-S250.
4. Le Liboux A. Lefebvre P, Le Roux Y, Truffinet P, Aubeneau M. Kirkesseli S and Montay G. Single- and multiple-dose pharmacokinetics of riluzole in white subjects. Journal of Clinical Pharmacology 1997; 37: 820-827.
5. Le Liboux A, Cachia JP, Kirkesseli S, Gautier JY, Guimart C, Montay G, Peeters PAM, Groen E, Jonkman JHG and Wemer J. A comparison of the pharmacokinetics and tolerability of riluzole after repeat dose administration in healthy elderly and young volunteers. Journal of Clinical Pharmacology 1999; 39: 480-486.